10-Q: Pacira Bio Q2 Loss Due to Investment Impairment, Restructuring

Pacira BioSciences reports a net loss for Q2 2025 due to investment impairment and restructuring charges, despite increased revenues.

Summary

• Pacira BioSciences reports a net loss of $4.8 million for Q2 2025, compared to a net income of $18.9 million in Q2 2024.
• Net product sales increased by 2% to $180.3 million in Q2 2025, driven by EXPAREL sales, but offset by decreased bupivacaine liposome injectable suspension sales.
• Operating expenses increased by 15% to $172.6 million, due to higher research and development, and selling, general and administrative costs.
• The company recognized a $10.7 million other net loss, primarily due to an impairment of an equity investment and convertible note receivable.
• A restructuring plan, including decommissioning a manufacturing suite, is expected to reduce annual operating expenses by approximately $13.0 million.
• The company entered into a co-promotion agreement with Johnson & Johnson MedTech to expand the market reach of ZILRETTA.

Sentiment

Score: 4

Explanation: The filing contains mixed sentiment. While revenue increased, the company reported a net loss and faces challenges related to global economic conditions and manufacturing efficiencies. The strategic collaboration with Johnson & Johnson MedTech is a positive development, but the overall tone is cautiously optimistic.

Positives

• Net product sales increased by 2% to $180.3 million in Q2 2025, driven by EXPAREL sales.
• EXPAREL revenue increased 4% in both the three and six months ended June 30, 2025 versus 2024.
• Gross margin increased to 77% in Q2 2025 from 75% in Q2 2024, due to lower EXPAREL inventory reserves and improved product costs.
• The company entered into a co-promotion agreement with Johnson & Johnson MedTech to expand the market reach of ZILRETTA.
• The USPTO issued U.S. Patent No. 12,318,483 claiming composition of EXPAREL manufactured by an enhanced process from our large-scale batch process in San Diego, California, which demonstrated a more consistent stability profile as measured by an in-vitro release assay (IVRA).
• The USPTO also issued U.S. Patent No. 12,296,047 claiming EXPAREL composition.
• The company secured a favorable reexamination result of U.S. Patent No. 11,033,495 from the USPTO.

Negatives

• The company reports a net loss of $4.8 million for Q2 2025, compared to a net income of $18.9 million in Q2 2024.
• Operating expenses increased by 15% to $172.6 million, due to higher research and development, and selling, general and administrative costs.
• The company recognized a $10.7 million other net loss, primarily due to an impairment of an equity investment and convertible note receivable.
• Bupivacaine liposome injectable suspension revenue decreased 84% and 45% in the three and six months ended June 30, 2025 versus 2024, respectively, due to timing of orders placed.
• The company decommissioned its 45-liter EXPAREL batch manufacturing suite located in San Diego and reduced its workforce accordingly.

Risks

• Direct and indirect effects of global economic conditions have in the past, and may continue to, negatively impact our business, financial condition and results of operations.
• The active pharmaceutical ingredient for both EXPAREL and ZILRETTA are sourced from outside the U.S.
• The U.S. and the European Union, or E.U., agreed to a trade deal that sets a 15% tariff on imports from the E.U., including branded pharmaceuticals, subject to Section 232 of the Trade Expansion Act of 1962.
• The company is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, tariffs, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.

Future Outlook

The company expects to continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera in additional procedures; progress our earlier-stage product candidate pipeline; advance regulatory activities for EXPAREL, ZILRETTA, iovera, PCRX-201 and our other product candidates; invest in sales and marketing resources for EXPAREL, ZILRETTA and iovera; expand and enhance our manufacturing capacity for EXPAREL, ZILRETTA and iovera; invest in products, businesses and technologies; and support legal matters.

Management Comments

• We expect to continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera in additional procedures.
• We are advancing a Phase 3 registration study to evaluate the safety and efficacy of ZILRETTA for the management of OA pain of the shoulder.
• We are currently sponsoring a prospective, real-world registry called the Innovations in Genicular Outcomes Registry, or IGOR, which is a patient-focused registry governed in collaboration with a steering committee of scientific experts that evaluates clinical, economicand health-related patient-reported outcomes in patients who have received any treatment for knee OA pain, including TKA, for a minimum of 18 months.

Industry Context

The report highlights the company's focus on non-opioid pain management and regenerative health solutions, aligning with the broader industry trend towards reducing opioid reliance and developing innovative therapies for osteoarthritis and other pain conditions. The collaboration with Johnson & Johnson MedTech reflects a strategic move to expand market reach and capitalize on the growing demand for non-opioid pain management options.

Comparison to Industry Standards

• ZILRETTA is the first and only extended-release, single-shot corticosteroid IA injection therapy for OA knee pain, giving it a competitive advantage over traditional immediate-release corticosteroids.
• The HCAd vector platform is much more efficient at delivering genes into cells compared to many other gene therapies that rely on adenovirus associated virus, or AAV, vectors.
• The vector used in the HCAd platform can carry up to 30,000 base pairs of DNA, which enables gene therapy with multiple or larger genes compared to AAV vectors.
• Genetic medicines based on the HCAd platform can be administered locally and have the potential for redosing at therapeutically appropriate intervals.

Legal Proceedings

• In January 2025, the Court issued its decision, finding that the disputed milestones were not met and therefore granted judgment to the Company in full in the MyoScience Milestone Litigation.
• On April 7, 2025, the Company, along with its operating subsidiary, Pacira Pharmaceuticals, Inc., entered into a settlement agreement with the ANDA filers with respect to the litigations noted above.
• On January 13, 2025, Leandro Alvarez filed a putative class action on behalf of Company shareholders between August 2, 2023 and August 8, 2024 against the Company and certain of its officers, in the District Court of New Jersey (25-cv-322).
• On June 16, 2025, a Shareholder Derivative suit, Young v. Lee, et al, was filed in the District of New Jersey (25-cv-11841).
• In April 2025, the Court issued judgment in favor of the Company in the Research Development Foundation litigation.

Stakeholder Impact

• Shareholders: Impacted by the net loss and share repurchase program.
• Employees: Impacted by the reduction in force at the San Diego facility.
• Customers: May benefit from the expanded market reach of ZILRETTA through the collaboration with Johnson & Johnson MedTech.
• Patients: May benefit from the development of new therapies and expanded indications for existing products.

Next Steps

• Advance a Phase 2 clinical study in knee OA.
• Advance a Phase 3 registration study to evaluate the safety and efficacy of ZILRETTA for the management of OA pain of the shoulder.
• Continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera in additional procedures.
• Continue to invest in clinical and preclinical development programs throughout 2025.

Key Dates

Recommendation

Given the mixed results, including a net loss offset by revenue growth and strategic initiatives, a hold recommendation is appropriate. The company's future performance will depend on the success of its pipeline development, commercialization efforts, and cost management strategies.

Keywords

Pacira BioSciences, EXPAREL, ZILRETTA, iovera, Financial Results, Q2 2025, SEC Filing, PCRX-201, Revenue, Net Loss, Restructuring, Pharmaceuticals, Biotech